A Phase IIb Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD5004 in Participants Living with Obesity or Overweight with Comorbidity

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513691-18-00

Acronym

D7260C00001

Enrollment

Registered

2024-10-14

Start date

2024-12-11

Completion date

2025-11-20

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Participants living with Obesity or Overweight with at least 1 comorbidity

Brief summary

Percent change in body weight from baseline at Week 26, Proportion of participants with weight loss ≥ 5% from baseline weight at Week 26

Detailed description

Percent change in body weight from baseline at Week 36, Proportion of participants with weight loss ≥ 5% at Week 36, Absolute change from baseline in body weight at Week 26 and at Week 36, Proportion of participants with weight loss ≥ 10% as well as ≥ 15% at Week 26 and at Week 36

Interventions

DRUGAZD5004

DRUGPlacebo to match AZD5004 film coated tablet

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percent change in body weight from baseline at Week 26, Proportion of participants with weight loss ≥ 5% from baseline weight at Week 26	—

Secondary

Measure	Time frame
Percent change in body weight from baseline at Week 36, Proportion of participants with weight loss ≥ 5% at Week 36, Absolute change from baseline in body weight at Week 26 and at Week 36, Proportion of participants with weight loss ≥ 10% as well as ≥ 15% at Week 26 and at Week 36	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026